China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
HKG: 0867
Neurodawn Pharmaceutical and China Medical System Holdings Ink Licensing Deal for Y-3
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has entered into a significant licensing deal with China Medical...
China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures
China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China
Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea
China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...